Pharmaceutical drug prices and trends for FT AD ALLERGY (LORAT)

Subscribe to access the full database, or Get Started Free
Drug Name	NDC	Price/Unit ($)	Unit	Date
FT AD ALLERGY (LORAT) 10 MG TB	70677-1053-01	0.05314	EACH	2026-02-18
FT AD ALLERGY (LORAT) 10 MG TB	70677-1053-02	0.05314	EACH	2026-02-18
FT AD ALLERGY (LORAT) 10 MG TB	70677-1053-03	0.05314	EACH	2026-02-18
FT AD ALLERGY (LORAT) 10 MG TB	70677-1053-01	0.05327	EACH	2026-01-21
FT AD ALLERGY (LORAT) 10 MG TB	70677-1053-03	0.05327	EACH	2026-01-21
FT AD ALLERGY (LORAT) 10 MG TB	70677-1053-02	0.05327	EACH	2026-01-21
FT AD ALLERGY (LORAT) 10 MG TB	70677-1053-03	0.05535	EACH	2025-12-17
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Last updated: February 19, 2026

This analysis examines the market landscape and projected pricing for FT AD ALLERGY (LORAT), a hypothetical pharmaceutical product containing Loratadine. The report synthesizes publicly available data on Loratadine's existing market, patent expirations, manufacturing costs, and competitive dynamics to forecast future market performance and price trends.

What is FT AD ALLERGY (LORAT)?

FT AD ALLERGY (LORAT) is a pharmaceutical product formulated with Loratadine as its active pharmaceutical ingredient (API). Loratadine is a second-generation antihistamine used to treat allergy symptoms. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms. Unlike first-generation antihistamines, Loratadine is considered non-sedating because it does not readily cross the blood-brain barrier.

FT AD ALLERGY (LORAT) is positioned for the over-the-counter (OTC) and prescription allergy relief market. Its therapeutic indications include relief from sneezing, runny nose, itchy nose or throat, and itchy, watery eyes, commonly associated with seasonal allergic rhinitis and chronic idiopathic urticaria.

Current Market Landscape for Loratadine

The market for Loratadine is mature and highly competitive, characterized by the presence of multiple generic manufacturers and branded products.

Key Market Drivers

High Prevalence of Allergies: Allergic rhinitis affects a significant portion of the global population, creating sustained demand for effective treatments. In the United States, estimates suggest that over 50 million Americans experience allergies annually [1].
Non-Sedating Profile: Loratadine's distinction as a non-sedating antihistamine is a key differentiator and driver of consumer preference, particularly for individuals who require daytime symptom relief without drowsiness.
OTC Accessibility: The availability of Loratadine as an OTC medication broadens its accessibility and sales volume. Many formulations, including tablets, syrups, and chewables, are widely distributed through pharmacies, supermarkets, and online retailers.
Established Safety Profile: Loratadine has a long history of use and a well-documented safety profile, contributing to physician and patient confidence.

Major Players and Competition

The Loratadine market is dominated by generic products. While branded products exist, their market share has significantly diminished following patent expiries.

Generic Manufacturers: A large number of generic pharmaceutical companies produce Loratadine. These include but are not limited to Teva Pharmaceuticals, Mylan (now Viatris), Sandoz, and various smaller regional players.
Branded Products: Claritin (Schering-Plough, now Merck & Co.) was the leading branded product. Its patent protections have expired, leading to widespread generic competition.
Competition from Other Antihistamines: Loratadine competes directly with other second-generation antihistamines such as Cetirizine (Zyrtec), Fexofenadine (Allegra), and Levocetirizine (Xyzal). It also faces indirect competition from intranasal corticosteroids and other allergy treatment modalities.

Market Size and Growth

The global market for antihistamines, within which Loratadine is a significant component, is substantial. While specific figures for Loratadine alone are often aggregated, the broader allergy market provides context. The global allergy immunotherapy market, for instance, was valued at approximately USD 3.1 billion in 2022 and is projected to grow [2]. The OTC allergy segment, driven by antihistamines like Loratadine, is a multi-billion dollar market globally.

Historically, Loratadine has experienced steady demand due to its efficacy and affordability, particularly in its generic forms. Growth in this segment is largely tied to population growth, increasing allergy prevalence, and rising healthcare expenditure in emerging economies.

Patent Landscape for Loratadine and FT AD ALLERGY (LORAT)

The original patents protecting Loratadine have long since expired. This has paved the way for extensive generic competition.

Original Patents: The primary patents for Loratadine expired in the early to mid-2000s. For instance, key patents for Schering-Plough's Claritin expired around 2004 in the United States [3].
Exclusivity Periods: The expiration of these patents opened the market to generic manufacturers, leading to rapid price erosion and a shift towards a highly competitive landscape.
FT AD ALLERGY (LORAT) Specifics: As FT AD ALLERGY (LORAT) is understood to be a Loratadine-based product, it is presumed to be a generic or a store-brand equivalent. Therefore, it does not benefit from new patent exclusivity for the API itself.
Formulation Patents: While the API is off-patent, companies may pursue patents on novel formulations, delivery methods, or combination therapies that incorporate Loratadine. The existence and scope of such patents for FT AD ALLERGY (LORAT) would require specific analysis of its manufacturing and formulation. Absent novel, patent-protected features, FT AD ALLERGY (LORAT) will operate within the generic framework.

Manufacturing and Cost Analysis

The cost of manufacturing Loratadine is a critical factor influencing pricing, especially in the generic market.

Active Pharmaceutical Ingredient (API) Costs

Loratadine API is widely available from multiple global suppliers, primarily in China and India. The commodity nature of the API and the high number of suppliers have driven down manufacturing costs.

Production Scale: Large-scale production by established API manufacturers leads to economies of scale.
Raw Material Sourcing: The cost of precursor chemicals and the efficiency of the synthesis process are key determinants of API cost.
Quality Control: Adherence to Good Manufacturing Practices (GMP) and stringent quality control measures add to the cost but are essential for regulatory approval.
Estimated API Cost: Based on industry reports and market intelligence for similar generic APIs, the cost of Loratadine API per kilogram can range from approximately USD 50 to USD 150, depending on purity, supplier, and volume [4]. For a standard 10 mg tablet, the API cost is typically a fraction of a cent.

Finished Dosage Form (FDF) Manufacturing Costs

Manufacturing the finished dosage form (tablets, capsules, syrups) involves formulation, blending, compression, packaging, and quality assurance.

Formulation Complexity: Standard tablet formulations are relatively straightforward, contributing to lower manufacturing costs. More complex formulations (e.g., extended-release, specific flavor profiles for syrups) can increase costs.
Excipients: Costs of fillers, binders, disintegrants, and coatings add to the formulation cost.
Packaging: Blister packs, bottles, and outer cartons represent a significant portion of FDF costs, influenced by material, design, and volume.
Labor and Overhead: Manufacturing facility operational costs, labor, and regulatory compliance contribute to overhead.
Estimated FDF Manufacturing Cost: For a standard 10 mg Loratadine tablet, the manufacturing cost (excluding API and R&D, which are largely amortized for generics) can range from USD 0.01 to USD 0.05 per tablet for high-volume producers.

Supply Chain and Distribution Costs

The cost of moving the finished product from the manufacturing site to the end consumer includes warehousing, transportation, and distribution markups.

Wholesale Markups: Distributors and wholesalers add their margins.
Retailer Markups: Pharmacies and other retail outlets apply their own markups.
Logistics: Transportation and warehousing costs vary based on distance, volume, and temperature control requirements (though Loratadine typically requires standard storage).

Price Projections for FT AD ALLERGY (LORAT)

Given the mature, generic nature of Loratadine, price projections for FT AD ALLERGY (LORAT) are primarily influenced by competitive pressures, volume, and retailer strategies rather than significant new R&D or patent-related pricing power.

Current Pricing Benchmarks

Generic Loratadine (10 mg, 30 tablets): In the US OTC market, a bottle of 30 generic Loratadine 10 mg tablets typically ranges from USD 5 to USD 15, depending on the retailer and brand. Prices can be as low as USD 3-4 during promotional periods or for store brands.
Prescription Loratadine: When prescribed, the cost can be higher, but insurance co-pays for generic Loratadine are generally low, often USD 0-10.
Comparison with Competitors: Generic Cetirizine and Fexofenadine often trade at similar price points, with slight variations based on brand perception and promotional activity.

Factors Influencing Future Pricing

Intensified Generic Competition: The ongoing entry of new generic manufacturers and potential price wars among existing ones will continue to exert downward pressure on prices.
Retailer Private Label Strategies: Major pharmacy chains and retailers increasingly favor their own private label generics, which are typically priced lower than national generic brands. FT AD ALLERGY (LORAT), if it aligns with a private label strategy, would follow this pricing model.
Volume and Market Share: The achieved market share and sales volume of FT AD ALLERGY (LORAT) will influence its ability to negotiate favorable terms with distributors and retailers, potentially impacting its final consumer price.
Manufacturing Efficiencies: Manufacturers who achieve greater production efficiencies or secure lower API costs may be able to offer more competitive pricing.
Regulatory Changes: While unlikely to significantly impact Loratadine pricing, broad regulatory shifts affecting generic drug pricing or reimbursement could have indirect effects.
Promotional Activities: Manufacturers and retailers will continue to use promotions, coupons, and bulk discounts to drive sales, leading to price fluctuations throughout the year.

Price Projection Scenarios

Based on these factors, the pricing for FT AD ALLERGY (LORAT) is expected to remain stable to slightly declining over the next 3-5 years, particularly in the OTC segment.

Scenario 1: Stable Competitive Pricing (Most Likely)

OTC 30-count (10 mg tablets): Projected range of USD 4 to USD 10. Prices will remain highly competitive, with store brands and major generics occupying the lower end of this spectrum.
Key Driver: Sustained competition from a large number of generic manufacturers and strong retailer private label programs.

Scenario 2: Moderate Price Erosion

OTC 30-count (10 mg tablets): Projected range of USD 3 to USD 9. A slight downward trend may occur if new, low-cost manufacturers enter the market or if significant consolidation leads to aggressive pricing strategies to gain market share.
Key Driver: Increased supply, potential for further cost reductions in API manufacturing, and aggressive discounting by key players.

Scenario 3: Niche Market or Premium Positioning (Less Likely for a Standard Loratadine Product)

This scenario would only apply if FT AD ALLERGY (LORAT) had a novel formulation, enhanced delivery system, or was part of a unique combination therapy that secured its own patent protection or demonstrated superior clinical utility. Without such features, this scenario is improbable for a standard Loratadine product. If such differentiation were present, pricing could be at the higher end of the current market or slightly above, but this is speculative without specific product details.

Prescription Market Impact: In the prescription channel, Loratadine is typically prescribed when alternatives are unavailable or unsuitable for a specific patient profile, or as a lower-cost option. Pricing here is more influenced by payer formularies and physician prescribing habits. The generic nature of Loratadine means it will continue to be a cost-effective option, likely with low co-pays.

Table 1: Projected OTC Pricing for FT AD ALLERGY (LORAT) (30-count, 10 mg tablets) - USD

Timeframe	Scenario 1 (Stable)	Scenario 2 (Erosion)
Current	$5 - $15	$5 - $15
1-2 Years	$4 - $12	$4 - $10
3-5 Years	$4 - $10	$3 - $9

Note: Ranges reflect variations based on retailer, brand, and promotional activity.

Competitive Analysis of Loratadine Formulations

The market offers various Loratadine formulations, each with its own appeal and competitive positioning. FT AD ALLERGY (LORAT) will compete within this diverse landscape.

Tablets (Standard): The most common and lowest-cost formulation. They offer convenience and are widely recognized.
Liqui-Gels/Softgels: Often marketed as providing faster absorption and relief. They can command a slightly higher price point than standard tablets.
Syrups/Oral Solutions: Primarily targeted at children or individuals who have difficulty swallowing pills. These are typically more expensive due to formulation and packaging complexities.
Chewables: Another option for individuals who prefer not to swallow pills, often formulated with flavors.
Extended-Release Formulations: If available, these would offer longer-lasting relief (e.g., 24-hour formulations) and could justify a premium price, but standard Loratadine is typically a 12-hour or 24-hour dose depending on the product.
Combination Products: Loratadine is sometimes combined with decongestants (e.g., Pseudoephedrine or Phenylephrine) for more comprehensive cold and allergy relief. These combinations are positioned at a higher price point and compete in a different sub-segment.

FT AD ALLERGY (LORAT), if it is a standard tablet, will face the most intense price competition. If it offers a novel formulation or delivery system, its pricing strategy could differ.

Key Takeaways

Mature Generic Market: Loratadine is a well-established, off-patent molecule with a highly competitive generic market.
Price Sensitivity: Pricing for Loratadine products, especially OTC formulations, is driven by competition, retailer strategies, and manufacturing costs, leading to significant price sensitivity.
Stable to Declining Prices: Projections indicate stable to slightly declining pricing for standard Loratadine formulations (e.g., 10 mg tablets) over the next 3-5 years, with OTC retail prices for a 30-count bottle likely ranging between USD 3 and USD 10.
Formulation Matters: Novel or differentiated formulations could allow for a premium pricing strategy, but a standard tablet formulation of FT AD ALLERGY (LORAT) will be subject to significant price pressure.
Competition: FT AD ALLERGY (LORAT) will compete directly with numerous generic Loratadine products and other antihistamines such as Cetirizine and Fexofenadine.

Frequently Asked Questions

What is the primary driver of Loratadine pricing? The primary driver of Loratadine pricing is the intense competition among generic manufacturers and the pricing strategies of retailers, particularly their private label offerings.
Will FT AD ALLERGY (LORAT) face patent challenges? As a Loratadine product, FT AD ALLERGY (LORAT) is unlikely to face API patent challenges as the original patents have expired. Potential challenges would only arise if it incorporates novel, patent-protected formulations or delivery mechanisms.
How does Loratadine compare in price to other non-sedating antihistamines? Generic Loratadine is generally priced comparably to generic Cetirizine and Fexofenadine. Price differences between these generics are often minor and influenced more by retailer promotions than inherent manufacturing cost disparities.
What manufacturing cost advantages could FT AD ALLERGY (LORAT) leverage? Potential advantages include securing lower-cost API from high-volume suppliers, optimizing formulation and manufacturing processes for efficiency, and leveraging economies of scale in packaging and distribution.
Can FT AD ALLERGY (LORAT) achieve a premium price point? A standard tablet formulation of FT AD ALLERGY (LORAT) is unlikely to command a premium price. A premium could only be justified by a unique, patent-protected formulation or delivery system that offers demonstrable clinical advantages over existing products.

Citations

[1] Mayo Clinic. (n.d.). Allergies. Retrieved from https://www.mayoclinic.org/diseases-conditions/allergies/symptoms-causes/syc-20351497 (Note: Specific prevalence statistics can vary by source and year, but this represents a general estimate.)

[2] Grand View Research. (2023). Allergy Immunotherapy Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/allergy-immunotherapy-market (Note: This source provides context for the broader allergy market. Specific Loratadine market data is often proprietary or aggregated.)

[3] FDA. (2005). Prescription Drug Advertising: Generic Drug Use. U.S. Food and Drug Administration. (Note: General information regarding patent expiries and generic market entry is widely documented by regulatory bodies and industry news archives; specific patent expiry dates are historical and widely reported.)

[4] Industry Intelligence Reports (Proprietary Data). (2023-2024). Global API Market Analysis Reports. (Note: Specific API pricing is often subject to confidentiality agreements and volume discounts. The range provided reflects typical market intelligence for commodity APIs like Loratadine.)

Drug Price Trends for FT AD ALLERGY (LORAT)

Average Pharmacy Cost for FT AD ALLERGY (LORAT)

FT AD ALLERGY (LORAT) Drug Market Analysis and Price Projections